Breakthrough HAE treatment enters final Long-Term testing phase
Disease control
Not yet recruiting
This study continues testing ADX-324, an experimental treatment for hereditary angioedema (HAE), to see how safe and effective it is over a longer period. It's for people who already completed the main trial and have HAE types 1 or 2. Researchers will track side effects, count ho…
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC